Cargando…
Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease
Hirayama disease (HD) is characterized by the juvenile onset of unilateral or asymmetric weakness and amyotrophy of the hand and ulnar forearm and is most common in males in Asia. A perception of compliance with previous standards of diagnosis and treatment appears to be challenged, so the review is...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844368/ https://www.ncbi.nlm.nih.gov/pubmed/35178023 http://dx.doi.org/10.3389/fneur.2021.811943 |
_version_ | 1784651458997649408 |
---|---|
author | Wang, Hongwei Tian, Ye Wu, Jianwei Luo, Sushan Zheng, Chaojun Sun, Chi Nie, Cong Xia, Xinlei Ma, Xiaosheng Lyu, Feizhou Jiang, Jianyuan Wang, Hongli |
author_facet | Wang, Hongwei Tian, Ye Wu, Jianwei Luo, Sushan Zheng, Chaojun Sun, Chi Nie, Cong Xia, Xinlei Ma, Xiaosheng Lyu, Feizhou Jiang, Jianyuan Wang, Hongli |
author_sort | Wang, Hongwei |
collection | PubMed |
description | Hirayama disease (HD) is characterized by the juvenile onset of unilateral or asymmetric weakness and amyotrophy of the hand and ulnar forearm and is most common in males in Asia. A perception of compliance with previous standards of diagnosis and treatment appears to be challenged, so the review is to update on HD. First, based on existing theory, the factors related to HD includes, (1) cervical cord compression during cervical flexion, (2) immunological factors, and (3) other musculoskeletal dynamic factors. Then, we review the clinical manifestations: typically, (1) distal weakness and wasting in one or both upper extremities, (2) insidious onset and initial progression for 3–5 years, (3) coarse tremors in the fingers, (4) cold paralysis, and (5) absence of objective sensory loss; and atypically, (1) positive pyramidal signs, (2) atrophy of the muscles of the proximal upper extremity, (3) long progression, and (4) sensory deficits. Next, updated manifestations of imaging are reviewed, (1) asymmetric spinal cord flattening, and localized lower cervical spinal cord atrophy, (2) loss of attachment between the posterior dural sac and the subjacent lamina, (3) forward displacement of the posterior wall of the cervical dural sac, (4) intramedullary high signal intensity in the anterior horn cells on T2-weighted imaging, and (5) straight alignment or kyphosis of cervical spine. Thus, the main manifestations of eletrophysiological examinations in HD include segmental neurogenic damages of anterior horn cells or anterior roots of the spinal nerve located in the lower cervical spinal cord, without disorder of the sensory nerves. In addition, definite HD needs three-dimensional diagnostic framework above, while probable HD needs to exclude other diseases via “clinical manifestations” and “electrophysiological examinations”. Finally, the main purpose of treatment is to avoid neck flexion. Cervical collar is the first-line treatment for HD, while several surgical methods are available and have achieved satisfactory results. This review aimed to improve the awareness of HD in clinicians to enable early diagnosis and treatment, which will enable patients to achieve a better prognosis. |
format | Online Article Text |
id | pubmed-8844368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88443682022-02-16 Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease Wang, Hongwei Tian, Ye Wu, Jianwei Luo, Sushan Zheng, Chaojun Sun, Chi Nie, Cong Xia, Xinlei Ma, Xiaosheng Lyu, Feizhou Jiang, Jianyuan Wang, Hongli Front Neurol Neurology Hirayama disease (HD) is characterized by the juvenile onset of unilateral or asymmetric weakness and amyotrophy of the hand and ulnar forearm and is most common in males in Asia. A perception of compliance with previous standards of diagnosis and treatment appears to be challenged, so the review is to update on HD. First, based on existing theory, the factors related to HD includes, (1) cervical cord compression during cervical flexion, (2) immunological factors, and (3) other musculoskeletal dynamic factors. Then, we review the clinical manifestations: typically, (1) distal weakness and wasting in one or both upper extremities, (2) insidious onset and initial progression for 3–5 years, (3) coarse tremors in the fingers, (4) cold paralysis, and (5) absence of objective sensory loss; and atypically, (1) positive pyramidal signs, (2) atrophy of the muscles of the proximal upper extremity, (3) long progression, and (4) sensory deficits. Next, updated manifestations of imaging are reviewed, (1) asymmetric spinal cord flattening, and localized lower cervical spinal cord atrophy, (2) loss of attachment between the posterior dural sac and the subjacent lamina, (3) forward displacement of the posterior wall of the cervical dural sac, (4) intramedullary high signal intensity in the anterior horn cells on T2-weighted imaging, and (5) straight alignment or kyphosis of cervical spine. Thus, the main manifestations of eletrophysiological examinations in HD include segmental neurogenic damages of anterior horn cells or anterior roots of the spinal nerve located in the lower cervical spinal cord, without disorder of the sensory nerves. In addition, definite HD needs three-dimensional diagnostic framework above, while probable HD needs to exclude other diseases via “clinical manifestations” and “electrophysiological examinations”. Finally, the main purpose of treatment is to avoid neck flexion. Cervical collar is the first-line treatment for HD, while several surgical methods are available and have achieved satisfactory results. This review aimed to improve the awareness of HD in clinicians to enable early diagnosis and treatment, which will enable patients to achieve a better prognosis. Frontiers Media S.A. 2022-02-01 /pmc/articles/PMC8844368/ /pubmed/35178023 http://dx.doi.org/10.3389/fneur.2021.811943 Text en Copyright © 2022 Wang, Tian, Wu, Luo, Zheng, Sun, Nie, Xia, Ma, Lyu, Jiang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Wang, Hongwei Tian, Ye Wu, Jianwei Luo, Sushan Zheng, Chaojun Sun, Chi Nie, Cong Xia, Xinlei Ma, Xiaosheng Lyu, Feizhou Jiang, Jianyuan Wang, Hongli Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease |
title | Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease |
title_full | Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease |
title_fullStr | Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease |
title_full_unstemmed | Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease |
title_short | Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease |
title_sort | update on the pathogenesis, clinical diagnosis, and treatment of hirayama disease |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844368/ https://www.ncbi.nlm.nih.gov/pubmed/35178023 http://dx.doi.org/10.3389/fneur.2021.811943 |
work_keys_str_mv | AT wanghongwei updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT tianye updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT wujianwei updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT luosushan updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT zhengchaojun updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT sunchi updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT niecong updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT xiaxinlei updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT maxiaosheng updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT lyufeizhou updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT jiangjianyuan updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease AT wanghongli updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease |